3Q22 Investor Update

FOCUSED ON INITIATIVES TO DRIVE GROWTH Revenue, net (in millions) Tobacco $7.8 M 3Q21 Hemp/Cannabis $8.0 M 4Q21 +149% YoY $9.0 M 1022 $14.5 M $4.5 $10.0 2Q22 $19.4 M $7.9 $11.5 3Q22 ■ ■ Leveraging exceptional VLNⓇ pilot results, moving aggressively into multi-sate commercial launch program Ž ■ 22ND CENTURY GROUP ■ Focused on launching VLN® in at least 12 to 15 states within the next 12 months - now in 5 states with proven launch template Advancing GVB's capabilities to further differentiate its products, access new market opportunities and drive growth Every 1% share of the U.S. retail market equates to approximately $800 million in retail sales, which is $500 million in revenue for a premium cigarette manufacturer. Passed NSF International Audit for pharma-grade manufacturing Submitted Drug Master File to FDA to produce and supply APIs for medical and pharmaceutical industry Pursing ICH Q7 international certification Focused on revenue opportunities and expanding margins Plan in place to generate positive cash flow and EBITDA from GVB's operations to fund hemp/cannabis franchise growth and VLNⓇ expansion 23

View entire presentation